Measuring Spending Levels - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Measuring Spending Levels
Pharmaceutical Technology's annual survey on equipment and machinery reveals the spending levels and type of spending made in 2010 and planned for 2011.


Pharmaceutical Technology
Volume 35, Issue 3, pp. 50-62


Figure 3: Areas of highest planned expenditures for equipment and machinery in 2011. API is active pharmaceutical ingredient.
2011 planned expenditures. The survey showed higher 2011 planned spending for equipment and machinery for quality assurance/quality control, making this category the second-highest area of expenditures for 2011. Similar to actual spending in 2009 and 2010, equipment for solid-dosage manufacturing will be the highest area of planned spending in 2011; 29.3% of respondents said they plan to spend the most in this area (see Figure 3). The next highest area will be in equipment for quality assurance/quality control, with 22.0% of respondents reporting that this will be their company's area of highest expenditures for planned purchases of equipment and machinery in 2011, up from 14.9% of respondents that reported this area of their highest level of spend in 2010 (see Figure 2). Planned purchasing for equipment and machinery producing biologic-based APIs and parenteral manufacturing are the next strongest areas for spending in 2011; 13.8% of respondents each reported these areas as targets of their highest spending levels in 2011 (see Figure 3).

Interestingly, the survey showed some spending shifts in planned expenditures for 2011 compared with actual spending levels in 2010. In looking at the percentage of respondents that said that they were going to increase spending in certain product areas, more respondents will increase their spending in 2011 for equipment and machinery used in chemical API manufacturing, including continuous API manufacturing. The survey also showed that respondents will reduce their level of increases slightly for equipment for manufacturing solid-dosage forms, quality assurance/quality control, biologic APIs, parenterals, and continuous manufacturing for finished products.

In analyzing spending in equipment categories, the survey showed the following results for 2011 planned spending:

  • 34.1% will increase spending on solid-dosage equipment (39.6% did in 2010); 56.1% will keep it the same
  • 33.6% will increase spending on equipment and machinery for quality assurance/quality control (35.9% did in 2010); 57.0% will keep it the same
  • 30% will increase spending for chemical API manufacturing (27.6% did in 2010); 61.7% will keep it the same
  • 27.9% will increase spending for biologic API manufacturing (33.8% did in 2010); 62.3% will keep it the same
  • 27.6% will increase spending for API, high-potency/high-containment manufacturing (33.3% did in 2010); 58.2% will keep it the same
  • 27.5% will increase spending for parenteral/sterile/aseptic manufacturing (30.7% did in 2010); 60.9% plan to keep it the same
  • 27.4% will raise spending for finished product, high-potency/high-containment manufacturing (35.5% did in 2010); 56.5% will keep it the same
  • 23.6% will raise spending for continuous processing technology, API (11.9% did in 2010); 58.2% will keep it the same
  • 18.8% will raise spending for continuous processing, finished product; (31.2% did in 2010); 57.8% will keep it the same.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here